AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7693504
Drug: both active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both active drugs together (terfenadine and ipratropium bromide)
Trial: 7693504
Drug: placebo preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo preparations (by mouth and by nebulizer)
Trial: 3536171
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose sublingual therapy with house dust mite
Trial: 15755834
Drug: Wheat products
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat products fortified with 0 mg Zn (group Zn-0)
Trial: 15755834
Drug: Wheat products
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat products fortified with 3 mg Zn (group Zn-3)
Trial: 15755834
Drug: Wheat products
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat products fortified with 9 mg Zn (group Zn-9)
Trial: 12585143
Drug: Wuzi Yanzong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuzi Yanzong Pill (WZYZP)
Trial: 2328178
Drug: Edrophonium 0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.1, 0.2, 0.4 or 1 mg kg‐1
Trial: 20530934
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (2 g/day)
Trial: 9643568
Drug: Anthracycline‐AraC intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline‐AraC intensive chemotherapy
Trial: 9643568
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose AraC
Trial: 3063328
Drug: Two-antibody depleted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-antibody depleted grafts (T10B9 and T12A10)
Trial: 3063328
Drug: One-antibody depleted
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-antibody depleted grafts (T10B9)
Trial: 30307720
Drug: Mini dental
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini dental implants
Trial: 27649676
Drug: BIFICO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIFICO treatment (oral admission)
Trial: 27649676
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (primary disease treatment alone)
Trial: 15983319
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (simvastatin 20 mg daily after cerivastatin 0.4 mg daily)
Trial: 10699602
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks followed by a maintenance dose of 240 mg every month (n = 458)
Trial: 10699602
Drug: Total androgen
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total androgen ablation (TAA) via bilateral orchiectomy or triptorelin 3.75 mg every month combined with flutamide 250 mg three times daily (n = 457)
Trial: 9382545
Drug: Continuous hepatic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hepatic arterial infusion of 5‐FU (360 mg/m2/day x 5 days/week x 4 weeks)
Trial: 9382545
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of 5‐FU (360 mg/m2/day x 2 weeks)
Trial: 31492651
Drug: ozanimod 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ozanimod 1.0 mg
Trial: 31492651
Drug: ozanimod 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ozanimod 0.5 mg
Trial: 23840043
Drug: HIV-1 PENNVAX®-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) with electroporation
Trial: 23840043
Drug: HIV-1 PENNVAX®-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) without electroporation
Trial: 9225876
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 600 mg i.v. daily for 10 days
Trial: 3624669
Drug: Active pyridostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pyridostigmine (180 mg orally every 12 hours)
Trial: 23532240
Drug: EDTA chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA chelation (3 g of disodium EDTA, 7 g of ascorbate, B vitamins, electrolytes, procaine, and heparin) administered via 40 infusions of a 500-mL solution over 30 weeks (weekly for 30 weeks, then 10 infusions 2 to 8 weeks apart)
Trial: 23532240
Drug: Placebo (500-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500-mL solution) administered in the same regimen as the EDTA group
Trial: 18761646
Drug: Metformin (MET),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (MET), n = 15, dose: 1500 mg daily
Trial: 17405254
Drug: Combination IGF‐I/GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination IGF‐I/GH therapy
Trial: 17405254
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (normal saline solution)
Trial: 10767775
Drug: Denacen (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denacen (test formulation)
Trial: 10767775
Drug: Calcort (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcort (reference formulation)
Trial: 1678757
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone injection pen
Trial: 30171664
Drug: Immediate intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate intensive treatment (eyedrops containing drugs from three different classes combined with 360° laser trabeculoplasty)
Trial: 30171664
Drug: Commonly recommended
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commonly recommended stepped regimen (drug monotherapy in accordance with common glaucoma guidelines)
Trial: 22552037
Drug: DHA-enriched fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched fish oil (800 mg/d)
Trial: 22552037
Drug: Vegetable oil
RxNorm normalized name: Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable oil capsules without DHA
Trial: 18418808
Drug: Taper period
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper period after both training types
Trial: 2389061
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release vaginal polymer pessary containing 10 mg prostaglandin E2 (PGE2), designed to release 0.6 mg per hour in vivo
Trial: 1015181
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (5,000 U) administered 2 hours before surgery and every 8 hours for 6 days
Trial: 7073148
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no heparin treatment)
Trial: 30593689
Drug: BRP0.5: basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRP0.5: basal diet + 0.25 g BPO + 0.25 g RPO/kg diet
Trial: 30593689
Drug: BRP1.0: basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRP1.0: basal diet + 0.50 g BPO + 0.50 g RPO/kg diet
Trial: 30593689
Drug: BRP1.5: basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRP1.5: basal diet + 0.75 g BPO + 0.75 g RPO/kg diet
Trial: 25224814
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m²) and the same RT dose (66-70 Gy/2 Gy fraction/5 fractions weekly)
Trial: 25224814
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (RT) (66-70 Gy/2 Gy fraction/5 fractions weekly)
Trial: 25224814
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy (RT) (66-70 Gy/2 Gy fraction/6 fractions weekly)
Trial: 24484450
Drug: Salovum® (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salovum® (16 grams initially, followed by 8 g every 5 hours until recovery)
Trial: 24484450
Drug: Placebo (ordinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ordinary egg yolk mixed in oral rehydration salts)
Trial: 12966253
Drug: Treatment (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (not specified in the abstract)
Trial: 6404595
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined oral contraceptive (ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg)
Trial: 30610027
Drug: Online, remotely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online, remotely delivered, therapist-supported exposure response prevention behavioural therapy for tics
Trial: 20437287
Drug: Education session
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education session on drug-to-drug interactions
Trial: 15767219
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg/day with telithromycin 800 mg/day
Trial: 15767219
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (single-dose) with telithromycin 800 mg/day
Trial: 12504970
Drug: Active management
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active management with oral misoprostol (50 microg every 4 hours, max 5 doses)
Trial: 12504970
Drug: Active management
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active management with oral misoprostol
Trial: 12504970
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management (induction with PGE(2) gel or oxytocin after 24 hours)
Trial: 9803051
Drug: Ayurvedic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic formulation (Misrakasneham)
Trial: 9803051
Drug: Conventional laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional laxative tablet (Sofsena)
Trial: 8613310
Drug: Furazolidone treatment
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone treatment
Trial: 25003812
Drug: Intramuscular clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular clodronate 100mg/week (CLO) (N=36)
Trial: 25003812
Drug: Yearly intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yearly intravenous therapy with 5mg zoledronate (ZOL) (N=18)
Trial: 15203809
Drug: Bupropion treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion treatment
Trial: 17895350
Drug: Extension-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extension-oriented treatment approach (EOTA)
Trial: 15354104
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between aspirin and clopidogrel
Trial: 12495795
Drug: Novel cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel cognitive-behavioral treatment (CBT)
Trial: 2260146
Drug: High-risk approach
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk approach with drugs to reduce risk factors in individuals with high levels
Trial: 6779673
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion of 7.8 microgram . kg‐1 . mn‐1 (Group I)
Trial: 6779673
Drug: No vasodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vasodilator drug (Group II)
Trial: 31813763
Drug: Pharmacist-led medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medicines review intervention (medicines education session, medicines optimisation session)
Trial: 31813763
Drug: Pharmacist-led medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medicines review intervention
Trial: 11837466
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2 grams elemental calcium daily from 20 weeks of gestation to delivery)
Trial: 9497178
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g psyllium seed husk (control)
Trial: 2529108
Drug: GR 38032F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR 38032F (0.15 mg/kg)
Trial: 1068646
Drug: Antimicrobial prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prophylaxis with oral nonabsorbed antibiotics and a nasal antibiotic ointment
Trial: 30528592
Drug: Ebola vaccine
RxNorm normalized name: ebola vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebola vaccine trial participants
Trial: 30528592
Drug: Adjuvanted seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted seasonal influenza vaccine trial participants
Trial: 23799922
Drug: LAN 90
RxNorm normalized name: melphalan 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAN 90 mg
Trial: 23799922
Drug: LAN 120
RxNorm normalized name: Calan 120mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAN 120 mg
Trial: 21406998
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 60-100 mg
Trial: 14734517
Drug: Selective adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective adenosine A2A receptor agonist binodenoson (various doses)
Trial: 25336668
Drug: CPVI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPVI + SVC-L
Trial: 16841676
Drug: Shenmai Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai Injection (SI) with chemotherapy
Trial: 8858271
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg N-acetylcysteine (NAC) for 4 months
Trial: 1620143
Drug: L-DOPA methyl
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA methyl ester
Trial: 29354929
Drug: Five needles
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five needles therapy
Trial: 22229478
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg p.o.
Trial: 20535920
Drug: Salviae injection
RxNorm normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salviae injection and ligustrazine injection (S & L) in combination with conventional Western medical treatment
Trial: 20535920
Drug: Salviae injection
RxNorm normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salviae injection and ligustrazine injection (S & L)
Trial: 8630464
Drug: Fast antipyrine
RxNorm normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast antipyrine metabolism in lung cancer patients and their first degree relatives
Trial: 8630464
Drug: Intermediate antipyrine
RxNorm normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate antipyrine metabolism
Trial: 8630464
Drug: Slow antipyrine
RxNorm normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow antipyrine metabolism
Trial: 1353720
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (250 micrograms/h for 96 h)
Trial: 1353720
Drug: Intramuscular Gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Gold salts
Trial: 1353720
Drug: Gold salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold salts for 8 months with Somatostatin infusion at the fourth month
Trial: 30627845
Drug: 9 serial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 serial mud baths within 21 days in addition to a multimodal physical rehabilitative complex treatment
Trial: 30627845
Drug: Only physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only physical rehabilitative treatment without mud baths
Trial: 17356110
Drug: Sildenafil therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil therapy for 3 months
Trial: 2892458
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg a day
Trial: 2892458
Drug: Betaxolol 20
RxNorm normalized name: betaxolol 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 20 mg a day
Trial: 29560570
Drug: Monthly vaginal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly vaginal ring
Trial: 29600595
Drug: Monthly intramuscular
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intramuscular injections
Trial: 29600595
Drug: Injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections
Trial: 29600595
Drug: Tablets and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and rings
Trial: 27294814
Drug: Mozart music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mozart music (Symphony No. 40 in g minor, KV 550)
Trial: 24552320
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg) plus chemotherapy (cisplatin-paclitaxel or topotecan-paclitaxel)
Trial: 24552320
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cisplatin-paclitaxel or topotecan-paclitaxel)
Trial: 1621496
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine sulphate
Trial: 1621496
Drug: 0.02 mg
RxNorm normalized name: escin 0.02 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg fentanyl citrate
Trial: 1621496
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg meperidine hydrochloride
Trial: 1621496
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml saline
Trial: 2418306
Drug: Oral nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicardipine
Trial: 28544215
Drug: Smooth neck
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smooth neck implant (1.5 mm)
Trial: 21815991
Drug: Rough neck
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough neck implant with grooves
Trial: 28544215
Drug: Scalloped rough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalloped rough neck implant with grooves
Trial: 26629926
Drug: Lactulose mannitol
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose mannitol solution
Trial: 26629926
Drug: Aspirin solution
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin solution (600 mg)
Trial: 26629926
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid solution (500 mg)
Trial: 26629926
Drug: Various solutions
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various solutions (lactulose mannitol, aspirin, ascorbic acid, blackcurrant)
Trial: 18855810
Drug: Topiramate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (300 mg/day)
Trial: 16790039
Drug: Minimal psychological
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal psychological intervention (MPI) administered by trained nurses
Trial: 12681876
Drug: Gemeprost (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemeprost (1 mg)
Trial: 8888329
Drug: 11 mg/day
RxNorm normalized name: ProStep 11 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 mg/day transdermal nicotine
Trial: 8888329
Drug: 22 mg/day
RxNorm normalized name: ProStep 22 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg/day transdermal nicotine
Trial: 8888329
Drug: 44 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 mg/day transdermal nicotine
Trial: 1511080
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine (CMI) 175-250 mg/day